🇺🇸 FDA

Company profile · Sponsor

Indivior

Indivior Europe Limited

INDV · NYSE pharma NORTH CHESTERFIELD, VA, GB
Pipeline
24
Drugs
2
Patents
8

Quick answer

Indivior (INDV) is a pharma company. headquartered in NORTH CHESTERFIELD, VA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker INDV
Exchange NYSE
Company type pharma
Headquarters NORTH CHESTERFIELD, VA, GB
SEC CIK 0001625297

Pipeline (24)

Search pipeline →

  1. Intranasal challenge drug

    Indivior

    Heroin Dependence

    phase 3 small molecule completed

    1 trial

  2. RBP-6000

    Indivior

    Opioid Use Disorder

    phase 3 small molecule completed

    4 trials

  3. RBP-7000

    Indivior

    Schizophrenia

    phase 3 small molecule completed

    5 trials

  4. SUBLOCADE

    Indivior

    Opioid Use Disorder

    phase 3 small molecule terminated

    2 trials

  5. SUBOXONE

    Indivior

    Opioid Dependence

    phase 3 small molecule completed

    1 trial

  6. SUBOXONE sublingual film

    Indivior

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  7. Arbaclofen Placarbil

    Indivior

    Alcohol Use Disorder

    phase 2 small molecule completed

    1 trial

  8. Buprenorphine

    Indivior

    Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  9. Buprenorphine hydrochloride marketed sublingual tablet (Subutex)

    Indivior

    Opioid Dependency

    phase 2 small molecule completed

    1 trial

  10. Buprenorphine soluble film

    Indivior

    Opioid-related Disorders

    phase 2 small molecule completed

    1 trial

  11. Buprenorphine/naloxone Film Strip

    Indivior

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  12. INDV-2000

    Indivior

    Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  13. INDV-6001

    Indivior

    Moderate to Severe Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  14. RBP-6000

    Indivior

    Opioid Related Disorder

    phase 2 small molecule completed

    1 trial

  15. RBP-6300

    Indivior

    Opioid Related Disorder

    phase 2 small molecule completed

    1 trial

  16. RBP-8000 100 mg

    Indivior

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  17. Risperidone

    Indivior

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  18. XP19986 CR

    Indivior

    GERD

    phase 2 small molecule completed

    1 trial

  19. Arbaclofen Placarbil SR

    Indivior

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. Buprenorphine Injectable Solution - Part A

    Indivior

    Healthy

    phase 1 small molecule completed

    1 trial

  21. INDV-2000

    Indivior

    Opioid Dependence

    phase 1 small molecule completed

    1 trial

  22. INDV-2000

    Indivior

    Healthy

    phase 1 small molecule completed

    1 trial

  23. INDV-6200

    Indivior

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

  24. [14C]IDV184001AN

    Indivior

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. buprenorphine

    BUPRENORPHINE NEURAXPHARM

    SUBCUTANEOUS approved

    N07BC51

  2. nalmefene hydrochloride

    REVEX

    INTRAMUSCULAR, SUBCUTANEOUS approved

Patents (8)

Search patents →

  1. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11839611

    Buprenorphine dosing regimens

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11712475

    Sustained delivery formulations of risperidone compound

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11135216

    Sublingual and buccal film compositions

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11110093

    Sustained release small molecule drug formulation

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11013809

    Sustained delivery formulations of risperidone compound

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11000520

    Buprenorphine dosing regimens

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10654842

    Dopamine D3 receptor antagonist compounds

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Indivior?

Indivior (INDV) is a pharma company. headquartered in NORTH CHESTERFIELD, VA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Indivior sponsor?

We track 24 ClinicalTrials.gov-linked programs for Indivior, including Intranasal challenge drug and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Indivior company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.